E ndothelial dysfunction is a pivotal early event in the development of atherosclerosis and a characteristic feature of obesity. This study was designed to investigate the effect of angiotensin-converting enzyme (ACE) inhibition on endothelial function in people who were obese but otherwise healthy. We performed a doubleblind, randomised, placebo-controlled study examining the effect of the ACE inhibitor perindopril (4 mg per day) on flow-mediated vasodilatation (FMD) of the brachial artery, arterial blood pressure, glucose homeostasis and inflammatory cytokines. Eighteen obese subjects (all body mass index > 30 kg/m 2 ) were randomised to receive perindopril or placebo for four weeks. Perindopril led to a fall in systolic blood pressure from 131 (standard error of mean [SEM] 3) to 117(5) mmHg and diastolic blood pressure from 74(4) mmHg to 68(4) mmHg, both p<0.001. Despite this fall in blood pressure, ACE inhibition had no effect on FMD, 8.2 (1.2)% versus 8.3 (1.5)%, p=0.9. ACE inhibition had no effect on insulin, lipids or circulating cytokines. In healthy obese humans, despite a significant reduction in blood pressure, ACE inhibition had no effect on FMD. Diabetes Vasc Dis Res 2006;3:34-8 
Introduction
It is well established that obesity is a risk factor for premature atherosclerosis. [1] [2] [3] Moreover, otherwise healthy obese subjects characteristically exhibit endothelial dysfunction, a hall-mark of early atherosclerosis. 4 Recently, we have demonstrated that amongst a range of lipid and non-lipid risk factors for endothelial dysfunction, waist-to-hip ratio is the only independent predictor of endothelial dysfunction. 5 The term endothelial dysfunction encompasses several potential abnormalities; the most extensively studied is a reduction in the bioavailability of nitric oxide (NO) . NO is an anti-atherosclerotic signalling molecule released by the vascular endothelium, which has potent vasodilatory, 6, 7 antiinflammatory, 8, 9 anti-proliferative, [10] [11] [12] antioxidant 13 and antiplatelet 14, 15 effects. A reduction in NO bioavailability is present in atherosclerotic vessels before vascular structural changes occur. Consonant with this, longitudinal studies have shown that impaired NO-dependent vasodilatation is a predictor of future cardiac events 16 and the development of coronary artery atherosclerosis. 17 Recently, the adipocyte has emerged as an important endocrine/paracrine organ, secreting peptides that may provide a direct link between obesity and endothelial dysfunction. These include the cytokines interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α) and the vasoactive peptide angiotensin II (AII). 4 Angiotensin-converting enzyme (ACE) inhibition, which blocks the formation of AII, reverses endothelial dysfunction in some of the individual conditions associated with obesity but its effect on subjects with obesity per se has not been studied. The aim of the present study was to examine the effect of ACE inhibition on endothelial function in obese but otherwise healthy humans.
Methods
Obese but otherwise healthy male or female subjects (body mass index [BMI] > 30 kg/m 2 ) were recruited from the staff of King's College Hospital London and from the local community by advertisement. None of the subjects were smokers or taking any medication. After baseline measurements, subjects were randomised to perindopril 2 mg or identical placebo (Sanofi Pharmaceuticals). Subjects returned one week later; the dose of perindopril was increased to 4 mg and renal function was checked. Measurements were repeated at the end of the four-week treatment period. All subjects had blood taken for measurement of lipids, glucose, insulin and inflammatory markers after a 12-hour fast and anthropometric measurements were performed before and after ACE inhibition. During the same visit subjects had assessment of brachial artery flow-mediated vasodilatation ORIGINAL ARTICLE
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(FMD) performed. All subjects completed the study, which was approved by the local ethics committee; all subjects gave written informed consent to take part in the study.
Plasma assays
Assays for serum high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol and glucose were performed in the hospital chemistry laboratory. Plasma insulin levels were assayed using radioimmunoassay. Serum samples for cytokine levels were stored at -80 o C until analysis. C-reactive protein (CRP) was measured using a high-sensitivity turbidimetric immunoassay (WAKO Chemicals, Neuss, Germany) on the Cobas Mira Analyser (Roche Diagnostics, Lewes, UK). The lowest concentration of CRP that could be detected was 0.2 mg/L. Within-batch variability was assessed and a coefficient of variation (CV) of 3.1% at 5.0 mg/L was achieved. TNF-α R2, a marker of bioactive TNF-α, and interleukin-6 (IL-6) were measured using commercially available enzyme-linked immunosorbent assays (R&D Systems, Minneapolis, MN, US). The CV for IL-6 was 12.7% and for TNF-α R2, 9%.
High-resolution ultrasonographic studies
Ultrasonographic studies were performed using a 12.5 MHz transducer (ATL Bothell, WA, US); a HDI 5,000-ultrasound machine was used for these studies. Subjects were asked to fast overnight. They then rested in a supine position for 10 minutes before the study and were kept supine during the procedure. In all studies the brachial artery was scanned longitudinally. The system used automatically acquires an electrocardiographically (ECG)-gated image of the brachial artery on every cardiac cycle. Blood pressure in the brachial artery of the left arm was recorded automatically at regular intervals (the mean of four readings was taken as the baseline blood pressure) and the ECG was recorded continuously.
The ultrasonographic protocol consisted of one-minute baseline imaging of the brachial artery diameter and Doppler blood flow velocity. After this a blood pressure cuff was placed round the right forearm and inflated to a pressure of 300 mmHg for four minutes, then deflated. Following cuff deflation, recordings were continued for one minute. Flow-mediated vasodilatation is expressed as the percentage change in the brachial artery diameter from baseline to 45-60 seconds after deflation of the cuff. Female subjects were studied in the follicular phase of the menstrual cycle, within one week of cessation of bleeding. All subjects visited the laboratory prior to the study to be familiarised with the technique. In our laboratory the coefficient of variation for repeated measures of brachial artery reactivity in lean subjects is < 16%. 5 Endothelium-independent vasodilatation was assessed using the vasodilatory response to sublingual GTN (400 µg).
Statistics
We recently demonstrated in severely obese humans that surgically induced weight loss leads to an almost 100% increase in flow-mediated vasodilatation. 18 Based on the standard deviation in the present cohort of obese subjects, results from eight subjects would provide 80% power to detect a 35% change in FMD. Data were assessed using Student's t-tests and expressed as mean (+SEM) or as median (with 95% confidence intervals). Non-normally distributed data were log transformed prior to analysis. Statistical significance was taken at the level of p<0.05. All analyses were performed using SPSS, Inc. version 9.0.
Results
Eighteen obese subjects took part in the study (for a detailed breakdown, see table 1). Randomisation led to 10 subjects receiving placebo (six had the metabolic syndrome according to National Cholesterol Education Program Adult Treatment Panel III [NCEP ATP III] criteria) and eight the ACE inhibitor (two had the metabolic syndrome according to NCEP ATP III criteria). As shown in the table, the subjects receiving placebo, though obese, had lower BMI and waist circumference than those receiving ACE inhibition. Perindopril significantly reduced the level of systolic and diastolic blood pressure (figure 1) but had no effect on any of the metabolic/inflammatory markers, FMD or endothelium-independent dilatation (table 1, figures 1 and 2). Placebo had no effect on any of the measured variables.
Discussion

Nitric oxide bioavailability and accelerated atherosclerosis
Compelling evidence supports endothelial dysfunction as a key early event in the pathogenesis of atherosclerosis. 19 ORIGINAL ARTICLE VOLUME 3 ISSUE 1 . MAY 2006 Obesity is characterised by endothelial dysfunction, 4 so approaches to improve endothelial function are therefore important. We have demonstrated that despite a significant improvement in blood pressure (demonstrating biological activity of ACE inhibition), ACE inhibition had no effect on endothelial function as assessed using measurement of flowmediated vasodilatation of the brachial artery.
Figure 1. Effect of one month's treatment with the angiotensin-converting enzyme inhibitor perindopril or placebo on: systolic blood pressure (A); diastolic blood pressure (B); Flow-mediated vasodilatation (C); GTNmediated vasodilatation (D). Data expressed as mean + SEM
ACE inhibition and endothelial dysfunction in obesity
Angiotensin II is thought to play a key role in the development of endothelial dysfunction in a variety of disease states. 20 Recent studies have demonstrated that all of the components of the renin-angiotensin system are expressed and produced by adipose tissue. 21 Furthermore, subjects with visceral obesity and the metabolic syndrome have a more active renin-angiotensin system. 22 Weight loss programmes are frequently unsuccessful and hence a pharmacological adjunct to improve vascular function is an attractive option. ACE inhibitors have been suggested as having favourable effects on the vascular wall beyond those of blood pressure reduction. 23 The Heart Outcomes Prevention Evaluation (HOPE) study suggested that the ACE inhibitor ramipril reduced cardiovascular events in patients at high risk, including type 2 diabetes patients, 24 by properties independent of blood pressure (although this hypothesis has since been challenged). 25 No study has explored the effect of ACE inhibition on endothelial dysfunction in 'pure' obesity.
Previous studies of the effect of ACE inhibition on endothelial function in type 2 diabetes patients have produced conflicting results. Bijlstra et al., 26 in a study of type 2 diabetics with hypertension, demonstrated no change in endothelial function in resistance vessels using perindopril for six months, despite a decline in blood pressure. In contrast to this O' Driscoll et al. 27 demonstrated an improvement in resistance vessel endothelial function after one month's treatment with enalapril in patients with type 2 diabetes.
In a randomised, double-blind trial we have demonstrated that despite reducing systolic blood pressure by ~17 mmHg and diastolic blood pressure by ~6 mmHg, ACE inhibition did not improve endothelial function in obese subjects. The difference between our data and those of O'Driscoll et al. may be accounted for by the fact that in O'Driscoll's study the patients were a heterogeneous group taking a variety of medications, including the insulin-sensitising agent metformin. Furthermore, in the study of O'Driscoll et al. body mass index or markers of fat distribution were not reported. Our dataset is in contrast to that of Lyons et al., 28 who demonstrated that a reduction in blood pressure using either the ACE inhibitor enalapril or the calcium channel blocker amlodipine improved basal NO production in resistance vessels. This raises the intriguing possibilities that resistance vessel endothelial function is more sensitive to changes in blood pressure and/or that basal rather than flowmediated NO release is more sensitive to changes in blood pressure. These possibilities warrant further attention.
Study limitations
The present study has a number of potential limitations. It is possible that a more prolonged treatment period might have resulted in an improvement in endothelial function. Moreover, the small group sizes may have missed minor changes in endothelial function in response to therapy. A crossover design might have increased the power of the study to detect small changes. However, to avoid potential problems with unpredictability of washout periods and more prolonged effects of ACE inhibition we used a parallel group study.
It would be interesting to assess the effect of more complete blockade of the actions of angiotensin using angiotensin receptor antagonists, which have been shown to improve endothelial function in hypertensive humans. 29 
Conclusions
In a recent study we demonstrated that weight loss led to a significant improvement in endothelial function, which was associated with an improvement in blood pressure, insulin sensitivity and inflammatory profile. 18 In the present report we demonstrated that, despite lowering blood pressure, ACE inhibition did not improve FMD. This suggests that increased activity of the renin-angiotensin system plays a relatively minor role in obesity-associated endothelial dysfunction. Increased fat mass is an integrated marker for a complex collection of vascular risk factors. To improve endothelial function in obesity, it seems we should be targeting several of these factors.
